|
1
|
Huang JF, Shen J, Li X, Rengan R,
Silvestris N, Wang M, Derosa L, Zheng X, Belli A, Zhang XL, et al:
Incidence of patients with bone metastases at diagnosis of solid
tumors in adults: A large population-based study. Ann Transl Med.
8:4822020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), . Adjuvant bisphosphonate treatment
in early breast cancer: Meta-analyses of individual patient data
from randomised trials. Lancet. 386:1353–1361. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gnant M, Pfeiler G, Steger GG, Egle D,
Greil R, Fitzal F, Wette V, Balic M, Haslbauer F,
Melbinger-Zeinitzer E, et al: Adjuvant denosumab in postmenopausal
patients with hormone receptor-positive breast cancer (ABCSG-18):
Disease-free survival results from a randomised, double-blind,
placebo-controlled, phase 3 trial. Lancet Oncol. 20:339–351. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fujii T, Mason J, Chen A, Kuhn P, Woodward
WA, Tripathy D, Newton PK and Ueno NT: Prediction of bone
metastasis in inflammatory breast cancer using a markov chain
model. Oncologist. 24:1322–1330. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
D'Oronzo S, Brown J and Coleman R: The
role of biomarkers in the management of bone-homing malignancies. J
Bone Oncol. 9:1–9. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coleman R, Hadji P, Body JJ, Santini D,
Chow E, Terpos E, Oudard S, Bruland Ø, Flamen P, Kurth A, et al:
Bone health in cancer: ESMO clinical practice guidelines. Ann
Oncol. 31:1650–1663. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Halleen JM, Tiitinen SL, Ylipahkala H,
Fagerlund KM and Väänänen HK: Tartrate-resistant acid phosphatase
5b (TRACP 5b) as a marker of bone resorption. Clin Lab. 52:499–509.
2006.PubMed/NCBI
|
|
8
|
Nenonen A, Cheng S, Ivaska KK, Alatalo SL,
Lehtimäki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P,
Sievänen H, et al: Serum TRACP 5b is a useful marker for monitoring
alendronate treatment: Comparison with other markers of bone
turnover. J Bone Miner Res. 20:1804–1812. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lumachi F, Basso SMM, Camozzi V, Tozzoli
R, Spaziante R and Ermani M: Bone turnover markers in women with
early stage breast cancer who developed bone metastases. A
prospective study with multivariate logistic regression analysis of
accuracy. Clin Chim Acta. 460:227–230. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nishimukai A, Higuchi T, Ozawa H, Yanai A,
Miyagawa Y, Murase K, Imamura M, Takatsuka Y and Miyoshi Y:
Different patterns of change in bone turnover markers during
treatment with bone-modifying agents for breast cancer patients
with bone metastases. Breast Cancer. 24:245–253. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wada N, Fujisaki M, Ishii S, Ikeda T and
Kitajima M: Evaluation of bone metabolic markers in breast cancer
with bone metastasis. Breast Cancer. 8:131–137. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chao TY, Yu JC, Ku CH, Chen MM, Lee SH,
Janckila AJ and Yam LT: Tartrate-resistant acid phosphatase 5b is a
useful serum marker for extensive bone metastasis in breast cancer
patients. Clin Cancer Res. 11:544–550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Clowes JA, Hannon RA, Yap TS, Hoyle NR,
Blumsohn A and Eastell R: Effect of feeding on bone turnover
markers and its impact on biological variability of measurements.
Bone. 30:886–890. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamada S, Inaba M, Kurajoh M, Shidara K,
Imanishi Y, Ishimura E and Nishizawa Y: Utility of serum
tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption
marker in patients with chronic kidney disease: Independence from
renal dysfunction. Clin Endocrinol (Oxf). 69:189–196. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gourgou-Bourgade S, Cameron D, Poortmans
P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J,
Bonnefoi H, et al: Guidelines for time-to-event end point
definitions in breast cancer trials: Results of the DATECAN
initiative (definition for the assessment of time-to-event
endpoints in CANcer trials). Ann Oncol. 26:873–879. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goldner W: Cancer-related hypercalcemia. J
Oncol Pract. 12:426–432. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liede A, Jerzak KJ, Hernandez RK, Wade SW,
Sun P and Narod SA: The incidence of bone metastasis after
early-stage breast cancer in Canada. Breast Cancer Res Treat.
156:587–595. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamashiro H, Takada M, Nakatani E, Imai S,
Yamauchi A, Tsuyuki S, Matsutani Y, Sakata S, Wada Y, Okamura R, et
al: Prevalence and risk factors of bone metastasis and skeletal
related events in patients with primary breast cancer in Japan. Int
J Clin Oncol. 19:852–862. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang Z and Hu C, Liu K, Yuan L, Li Y,
Zhao C and Hu C: Risk factors, prognostic factors, and nomograms
for bone metastasis in patients with newly diagnosed infiltrating
duct carcinoma of the breast: A population-based study. BMC Cancer.
20:11452020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Diessner J, Wischnewsky M, Stüber T, Stein
R, Krockenberger M, Häusler S, Janni W, Kreienberg R, Blettner M,
Schwentner L, et al: Evaluation of clinical parameters influencing
the development of bone metastasis in breast cancer. BMC Cancer.
16:3072016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lipton A, Chapman JA, Demers L, Shepherd
LE, Han L, Wilson CF, Pritchard KI, Leitzel KE, Ali SM and Pollak
M: Elevated bone turnover predicts for bone metastasis in
postmenopausal breast cancer: Results of NCIC CTG MA.14. J Clin
Oncol. 29:3605–3610. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rissanen JP, Suominen MI, Peng Z and
Halleen JM: Secreted tartrate-resistant acid phosphatase 5b is a
marker of osteoclast number in human osteoclast cultures and the
rat ovariectomy model. Calcif Tissue Int. 82:108–115. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Croucher PI, McDonald MM and Martin TJ:
Bone metastasis: The importance of the neighbourhood. Nat Rev
Cancer. 16:373–386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen HM, Chen FP, Yang KC and Yuan SS:
Association of bone metastasis with early-stage breast cancer in
women with and without precancer osteoporosis according to
osteoporosis therapy status. JAMA Netw Open. 2:e1904292019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Halleen JM, Ylipahkala H, Alatalo SL,
Janckila AJ, Heikkinen JE, Suominen H, Cheng S and Väänänen HK:
Serum tartrate-resistant acid phosphatase 5b, but not 5a,
correlates with other markers of bone turnover and bone mineral
density. Calcif Tissue Int. 71:20–25. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu H, Zhang X, Zhang S, Wang X and Yu S:
Factors associated with bone metastasis in breast cancer: A
systematic review and meta-analysis. Ann Palliat Med. 10:4435–4452.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu ZQ, Zhang Y, Xie E, Song WJ, Yang RX,
Yan CJ, Zhang BF and Xu HG: High uric acid (UA) negatively affects
serum tartrate-resistant acid phosphatase 5b (TRACP 5b)
immunoassay. PLoS One. 11:e01475542016. View Article : Google Scholar : PubMed/NCBI
|
